Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Ofatumumab

Nature Reviews Drug Discovery volume 9, pages 101–102 (2010)Cite this article

Subjects

Abstract

Ofatumumab (Arzerra; Genmab/GlaxoSmithKline) — a fully human cytolytic monoclonal antibody that is specific for CD20 — was approved by the US FDA for the treatment of chronic lymphocytic leukaemia in October 2009.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dighiero, G. & Hamblin, T. J. Chronic lymphocytic leukaemia. Lancet 371, 1017–1029 (2008).

    Article  CAS  Google Scholar 

  2. Zenz, T et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nature Rev. Cancer 10, 37–50 (2010).

    Article  CAS  Google Scholar 

  3. Christian, B. A. & Lin, T. S. Antibody therapy for CLL. Semin. Haematol. 45, 95–103 (2008).

    Article  CAS  Google Scholar 

  4. Avivi, I. et al. Clinical use of rituximab in haematological malignancies. Br. J. Cancer 89, 1389–1394 (2003).

    Article  CAS  Google Scholar 

  5. Teeling, J. L. et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. Blood 104, 1793–1800 (2004).

    Article  CAS  Google Scholar 

  6. Food and Drug Administration. FDA labelling information. FDA web site [online], (2009).

  7. Teeling, J. L. et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177, 362–371 (2006).

    Article  CAS  Google Scholar 

  8. Coiffier, B. et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood 111, 1094–1100 (2008).

    Article  CAS  Google Scholar 

  9. Hallek, M. et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood 114, 223 (abstract 535) (2009).

    Article  Google Scholar 

  10. Tam, C.S. et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leukemia Lymphoma 48, 1885–1887 (2007).

    Article  Google Scholar 

  11. Wierda, W. G. et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. Blood 114, 90 (abstract 207) (2009).

    Google Scholar 

  12. IMS MIDAS (IMS Health, 2009).

  13. Al-Wakeel, Y. et al. Credit Suisse Equity Research Report (Credit Suisse Security, 18 Nov 2009)

    Google Scholar 

  14. Welford, P. et al. Jefferies International Report (Jefferies International, 11 Nov 2009).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Michael J. Keating is at 1515 Holcombe Boulevard, Unit 428, Houston, Texas 77030, USA. mkeating@mdanderson.org,

    Michael J. Keating

  2. Argyris Dritselis and Uma Yasothan are at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK. ADritselis@be.imshealth.com,

    Argyris Dritselis & Uma Yasothan

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Michael J. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Argyris Dritselis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uma Yasothan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, M., Dritselis, A., Yasothan, U. et al. Ofatumumab. Nat Rev Drug Discov 9, 101–102 (2010). https://doi.org/10.1038/nrd3100

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3100

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research